HSPBAP1

Across TCGA pan-cancer cohorts, HSPBAP1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HSPBAP1 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HSPBAP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSPBAP1 expression acts as an unfavorable survival marker.

HNSC, LIHC, and CESC are the cancer types where HSPBAP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.078	0.680	<.001	20	view →
LIHC	OS	Median	All	0.204	0.777	.008	15	view →
CESC	OS	Median	II,III,IV	0.227	0.759	.029	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HSPBAP1–HNSC (DFS)

Open the HNSC breakdown →